Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Are Lilly, Novartis eyeing the PD-1xVEGF field? Execs weigh in
Both Eli Lilly and Novartis once had their PD-1 inhibitor dreams shattered, and both know the VEGF realm.
Angus Liu
Jun 4, 2025 1:00pm
Eli Lilly taps Camurus' tech to advance long-acting obesity meds
Jun 3, 2025 5:04pm
Lilly lands next-gen pain asset in $1B SiteOne acquisition
May 27, 2025 11:30am
Weight of market pressures pushes Novo CEO out—Chutes & Ladders
May 23, 2025 8:30am
Pharma-backed dementia fund raises $269M to invest in therapies
May 20, 2025 9:48am
Fierce Pharma
Novo's longtime CEO Lars Fruergaard Jørgensen to step down
May 16, 2025 9:41am
